Efficacy of topical ivermectin and impact on quality of life in patients with papulopustular rosacea: A systematic review and meta‐analysis. Issue 1 (2nd January 2020)

• Record Type: Journal Article
• Authors: Husein‐ElAhmed, Husein; Steinhoff, Martin
• Is Part Of: Dermatologic therapy. Volume 33:Issue 1(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-01-02
• Subjects: efficacy -- ivermectin -- papulopustular rosacea -- quality of life -- treatment; Skin -- Diseases -- Periodicals; Dermatology -- Periodicals; 616.5
• DOI: 10.1111/dth.13203
• Languages: English
• ISSNs: 1396-0296

Abstract

Abstract: Rosacea is a chronic dermatosis which affects negatively patients' quality of life (QoL). There is shortage of high‐quality evidence comparing the efficacy of ivermectin cream (IVM) 1% with other available topical choices. Besides, the well‐documented impaired of self‐esteem and stigmatization of rosacea patients make essential to address which treatment provides the greatest psychological and social benefit. Our objective is to critically review and appraise the efficacy of IVM 1% in PPR and the impact in patients' QoL against other options. We carried out a literature search from PubMed, MEDLINE, EMBASE, Cochrane, and clinicaltrials.gov using the following descriptors: "rosacea" AND "ivermectin." Efficacy was assessed with the Investigator Global Assessment (IGA), and the impact on QoL was based on the DLQI score. Six studies from four published articles were included. The meta‐analysis estimated that more participants achieved "success" (IGA ≤ 1) and "complete clearance" (IGA = 0) with IVM1%. The overall effect estimate for IGA ≤ 1 was: 1.56 [1.23–1.97], whereas for IGA = 0, it was: 1.72 [1.40–2.11]. The rate of participants achieving lower DLQI score, and thus, better QoL was with IVM 1%. The overall effect estimate was: 1.71 [1.34–2.18] at week 16# and 1.64 [1.38–1.94] at week 52#. This meta‐analysis confirms IVM 1% cream as the most effective topical treatment and it satisfies the impairment of social life with sustained better QoL. Further studies extending this period of remission are warranted, as well as researches about the potential application of this agent combined with other agents. KEY POINTS: Question: What is the current efficacy of ivermectin versus other choices in papulopustular rosacea and its impact on patients' quality of life? Findings: In this meta‐analysis, ivermectin showed higher efficacy than metronidazol, azelaic acid, and placebo measured by Investigator Global Assessment. Parallely, the DLQI score highlighted that this agent was more beneficious in both short and long‐term. Meaning: This meta‐analysis gives strong evidence that ivermectin is the most effective topical treatment. Besides, this agent provides the greatest psychological benefit as it satisfies the stigmatization of rosacea patients as well as the impairment of social and working life with a sustained better QoL above other alternatives.